| Aradhana Sarin |
Aradhana Sarin currently works at AstraZeneca PLC, as Chief Financial Officer & Executive Director from 2021 and Anheuser-Busch InBev SA, as Independent Non-Executive Director from 2023. Dr. Sarin also formerly worked at OraSure Technologies, Inc., as Independent Director, Achillion Pharmaceuticals, Inc., as President & Director, UBS AG, as Managing Director-Healthcare Investment Banking from 2004 to 2010, Citizens, Inc. (Austin, Texas), as MD-Healthcare Corporate & Investment Banking from 2010 to 2017, and Alexion Pharmaceuticals, Inc., as President, Chief Financial Officer & Executive VP from 2020 to 2021. Dr. Sarin received his doctorate degree from the University of Delhi and Masters Business Admin degree from Stanford Graduate School of Business. |
| Regina Fritsche-Danielson |
Regina Fritsche-Danielson currently works at Fluicell AB, as Director from 2022, SmartCella Holding AB, as Director, and AstraZeneca PLC, as SVP, Head-Research & Early Development. Dr. Fritsche-Danielson received her doctorate degree in 1993 from the University of Gothenburg. |
| Cindy L. Hoots |
Cindy L. Hoots is an Independent Director at Zoom Communications, Inc. since 2023. She is also the Chief Digital & Information Officer at AstraZeneca PLC since 2020. Previously, she worked as the VP-Next Generation Products & Commercial at British American Tobacco plc from 2016 to 2018, and as the Global Vice President-Technology at Unilever Plc from 2018 to 2019. Ms. Hoots completed her undergraduate degree at DeVry Institute of Technology. |
| Alberto Hegewisch |
Alberto Hegewisch is currently the Chief Medical Officer at AstraZeneca PLC since 2023. He completed his undergraduate degree at Universidad La Salle and his graduate degree at Hibernia College. |
| Sharon Barr |
Sharon Barr currently works at AstraZeneca PLC, as EVP-BioPharmaceuticals Research & Development from 2023. Ms. Barr also formerly worked at Alexion Pharmaceuticals, Inc., as Senior VP, Head-Research & Product Development from 2020 to 2021. |
| Jeffrey Pott |
Mr. Jeffrey Pott is a CHRO, Chief Compliance Officer & General Counsel at AstraZeneca PLC. Mr. Pott was previously employed as a Chairman by Aptium Oncology, Inc. and a Principal by Drinker Biddle & Reath LLP. He received his undergraduate degree from Wheaton College (Illinois) and a graduate degree from Villanova University School of Law. |
| Pam P. Cheng |
Pam P. Cheng currently works at Smiths Group Plc, as Independent Non-Executive Director from 2020, AstraZeneca PLC, as Executive VP-Operations & Information Technology from 2015, and Stevens Institute of Technology, as Trustee. Ms. Cheng also formerly worked at Codexis, Inc., as Independent Director from 2014 to 2020, Merck & Co., Inc., as Senior VP-Global Supply Chain Management from 2006 to 2011, and MSD China Holding Co. Ltd., as President from 2011 to 2015. Ms. Cheng received her undergraduate degree and graduate degree from Stevens Institute of Technology and Masters Business Admin degree from Pace University. |
| Marc Pierre Jean Dunoyer |
Marc Pierre Jean Dunoyer is currently the Chief Executive Officer at Alexion Pharmaceuticals, Inc. He is also the Chairman at AstraZeneca KK. In addition, he holds director positions at AstraZeneca UK Ltd., AstraZeneca Intermediate Holdings Ltd., Acerta Pharma BV, Orchard Therapeutics (Europe) Ltd., Cellectis SA, and JCR Pharmaceuticals Co., Ltd. He previously served as the Chief Strategy Officer at AstraZeneca PLC. Prior to his current roles, he was the Chairman at GlaxoSmithKline KK and Orchard Therapeutics Plc. He also held positions as the Outside Director at JCR Pharmaceuticals Co., Ltd. and President-Asia Pacific at Hoechst Marion Roussel SA. Additionally, he was the Global Head-Rare Diseases Unit at GSK Plc and worked at Societe Generale Strauss Turnbull Securities Ltd. Mr. Dunoyer holds an MBA from Hautes Etudes Commerciales and a graduate degree from Université de Paris IV Paris-Sorbonne. |
| Michel Demaré |
Michel Demaré currently works at AstraZeneca PLC, as Non-Executive Chairman from 2023, Louis Dreyfus Company Holdings BV, as Deputy Chairman-Supervisory Board, International Institute for Management Development, as Chairman-Supervisory Board, Nomoko AG, as Chairman, Vodafone Group Plc, as Non-Executive Director from 2018, and Beirat Zukunft Finanzplatz, as Member. Mr. Demaré also formerly worked at UBS Group AG, as Independent Vice Chairman from 2010 to 2019, Syngenta AG, as Vice Chairman-Supervisory Board in 2017, SwissHoldings, as Chairman from 2014 to 2015, Syngenta Foundation For Sustainable Agriculture, as Chairman from 2013 to 2017, UBS AG, as Vice Chairman-Supervisory Board from 2009 to 2019, Baxter International, Inc., as Chief Financial Officer-Europe Region from 2002 to 2005, The Dow Chemical Co., as CFO-Global Polyolefins & Elastomers Division from 1997 to 2002, and ABB Ltd., as Chief Financial Officer from 2005 to 2008. Mr. Demaré received his Masters Business Admin degree in 1980 from Katholieke Universiteit Leuven and undergraduate degree in 1978 from Université Catholique de Louvain. |
| José Baselga |
Founder of Venthera, Inc., Mosaic Biomedicals SL and Tango Therapeutics, Inc., José Baselga is an entrepreneur is on the board of Breast International Group and Foghorn Therapeutics, Inc. and Executive VP-Oncology Research & Development at AstraZeneca Plc, Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society of Clinical Investigation and Member of National Academy of Medicine of United States.
Dr. Baselga previously was President for American Association for Cancer Research, Chairman-Hematology & Oncology Division at The General Hospital Corp., Associate Director at Massachusetts General Hospital Cancer Center, President of European Society for Medical Oncology, Chief Medical Officer for Memorial Sloan-Kettering Cancer Center, Director at American Society of Clinical Oncology, Professor at Weill Cornell Medical College, Professor at Harvard Medical School and Director & Chairman-Medical Oncology Service at Vall d'Hebron Institut d'Oncologia.
José Baselga received a doctorate from Autonomous University of Barcelona. |
| Pascal Soriot |
Pascal Soriot currently works at AstraZeneca PLC, as Chief Executive Officer & Executive Director from 2012, AstraZeneca Pharmaceuticals LP, as Chief Executive Officer, AstraZeneca UK Ltd., as Chief Executive Officer & Director, AstraZeneca Holding GmbH, as Chief Executive Officer & Executive Director, AstraZeneca Österreich GmbH, as Chief Executive Officer, AstraZeneca Colombia SAS, as Chief Executive Officer & Director from 2012, AstraZeneca AB, as Chairman, The Sustainable Markets Initiative, as Director from 2023, Agilent Technologies, Inc., as Director from 2025, Pharmaceutical Research & Manufacturers of America, as Director, and Acerta Pharma BV, as Director. Dr. Soriot also formerly worked at Genentech, Inc., as Director & Chief Executive Officer-Roche Group in 2012, CSL Ltd., as Independent Non-Executive Director from 2020 to 2021, Chugai Pharmaceutical Co., Ltd., as Director from 2010 to 2011, Viela Bio, Inc., as Independent Director from 2019 to 2020, Roche Pharmaceuticals, Inc., as Chief Operating Officer from 2010 to 2012, Sanofi-Aventis U.S. LLC, as Chief Operating Officer in 2006, Hoechst Marion Rousel JP, as Vice President-Asia Pacific in 2000, and Roussel NZ Ltd., as Manager-District Sales in 1989. Dr. Soriot received his Masters Business Admin degree from École des Hautes Études Commerciales de Paris and doctorate degree from École Nationale Vétérinaire d'Alfort. |
